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Abstract 
 
 
Cardiovascular disease is highly prevalent on human immunodeficiency virus (HIV)-infected 
young adults, with serious implications on the choice of the most cardiovascular friendly 
antiretroviral regimen and its management. Nevirapine (NVP) is an antiretroviral drug that, 
although associated with hepatotoxicity and skin rash, is currently recognized as a high-density 
lipoprotein (HDL) booster in HIV-infected patients. This HDL booster effect is even more 
pronounced than the current available drugs for this purpose. However, besides HDL quantity, 
its quality is also essential. On this regard, the present study aims to give new insights into the 
effect of NVP on HDL quality, namely its antioxidant potential, which can be measured through 
the activities of its associated enzyme, paraoxonase-1 (PON1): paraoxonase (POase), 
arylesterase (AREase) and lactonase (LACase) activities. The role of PON1 as a protective 
player against the toxicity inherited to the use of NVP was also explored. Additionally, new 
methods were developed for the assessment of PON1 AREase and LACase activities. 
The study protocol received prior approval from the ethics committees of the hospitals and a 
total of 54 HIV-infected patients were included. 
The methods herein developed are reliable and suitable for monitoring PON1 AREase and 
LACase activities in human blood. 
The negative effect of NVP on PON1 activities is dependent from the formation its phase-I 
metabolites, especially 12-OH-NVP. The 3-OH-NVP seemed to be the safest metabolite. 
The current study gives new insights into the players on the mechanism of NVP-toxicity. 
Moreover, it provides evidence for the development of new NVP or its metabolites analogues, 
less toxic than NVP, which might in the future have a place in the border of HDL boosters. 
 
 
 
 
 
 
Keywords: cardiovascular disease and human immunodeficiency virus infection, 
high-density lipoprotein booster, high-density lipoprotein quality, nevirapine, nevirapine toxicity, 
paraoxonase-1 activities.
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Resumo 
 
 
A doença cardiovascular é altamente prevalente em jovens adultos infectados pelo vírus da 
imunodeficiência humana (VIH), com implicações sérias na escolha e gestão da terapêutica 
antiretroviral combinada mais adequada para a comorbilidade cardiovascular. A nevirapina 
(NVP) é um antiretroviral que, apesar de estar associado a toxicidade hepática e cutânea, é 
actualmente reconhecido por aumentar os níveis da lipoproteína de elevada densidade (HDL). 
Este efeito é mais pronunciado que o conseguido com os fármacos actualmente disponíveis 
para esse fim. No entanto, além da sua quantidade, a qualidade da HDL é também essencial. 
Desta forma, este estudo tem como objectivo demonstrar o efeito da NVP na qualidade da 
HDL, nomeadamente no seu potencial antioxidante, que pode ser medido através das três 
actividades do enzima paraoxonase-1 (PON1) que circula associado à HDL: paraoxonase 
(POase), arilesterase (AREase) e lactonase (LACase). O papel protector do PON1 contra a 
toxicidade associada à toma da NVP também foi explorado. Adicionalmente, foram 
desenvolvidos e validados novos métodos para a monitorização das actividades AREase e 
LACase do PON1. 
O protocolo do estudo foi previamente aprovado pela comissão de ética dos hospitais e 
foram incluídos um total de 54 doentes infectados pelo VIH positivo. 
Os métodos desenvolvidos são válidos e adequados para a monitorização das actividades 
AREase e LACase do PON1 em sangue humano. 
O efeito negativo da NVP nas actividades do PON1 é dependente da formação dos seus 
metabolitos de fase I, especialmente o 12-OH-NVP. O metabolito 3-OH-NVP foi o que menos 
influenciou a actividades do PON1. 
Este estudo permitiu identificar novos protagonistas no mecanismo da toxicidade induzida 
pela NVP. Além disso, abre portas ao desenvolvimento de novos análogos da NVP ou dos 
seus metabolitos, que sejam menos tóxicos que a própria NVP e que possam futuramente ser 
usados como moduladores da HDL. 
 
 
 
 
 
 
Palavras-Chave: actividades do paraoxonase-1, doença cardiovascular e a infecção pelo 
vírus da imunodeficiência humana, modulador da lipoproteína de elevada densidade, 
nevirapina, qualidade da lipoproteína de elevada densidade, toxicidade da nevirapina. 
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1.  Introduction
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1.1 Cardiovascular disease in human immunodeficiency virus 
infection: the virus and the antiretroviral drugs 
 
Nearly 34 million people are currently living with the human immunodeficiency virus (HIV)-infection, 
the cause of acquired immunodeficiency syndrome (AIDS) (WHO, 2013). HIV-infection is a chronic 
condition characterized by persistent infection and inflammation. The virus infects and depletes cluster 
of differentiation 4 (CD4) lymphocyte cells, resulting in immunodeficiency and on a slowly progressive 
disease (Shor-Posner et al., 1993; Riddler et al., 2003) that, if left untreated, has a high rate of 
morbidity and mortality (Tohyama et al., 2009). 
Though HIV-infection continues to spread, the survival of these patients is considerably extended 
by the combined antiretroviral therapy (cART). As so, the HIV population is getting older and it is likely 
that long-term consequences of both HIV-treatment and infection will become increasingly common 
(Parra et al., 2010a). The persistent infection/inflammation, residual viremia, compromised immune 
system, co-infections (e.g. tuberculosis and hepatitis), polimedication and drug-drug interactions, 
potentially along with antiretroviral (ARV)-toxicity, could place these patients at a particular increased 
risk of developing several complications, many of which are commonly associated with ageing. For 
instance, liver disease is often present in these patients, partly due to the high rates of chronic viral 
hepatitis and alcohol misuse, as well as long-term exposure to potentially hepatotoxic ARVs (Deeks 
and Phillips, 2009). Compelling data suggest that other diseases are more prevalent in HIV-infected 
patients than in age-matched uninfected people, such as cancer (Kirk et al., 2007) and bone disease 
(Arnsten et al., 2007). Also, neurological disease persists or even progresses during long-term 
treatment (McCutchan et al., 2007). Currently, cardiovascular disease (CVD) is turning into a 
preponderant condition in HIV-infected patients, as it has become a leading cause of morbidity and 
mortality in these patients (Triant et al., 2007; Hsue et al., 2008; Knudsen et al., 2012). 
 
With the implementation of cART in 1996, HIV-infection has changed from a lethal to a chronic 
disease in properly medicated patients (Deeks, 2009). The number of people receiving cART has 
tripled in the last five years and has reached in 2012 to 9.7 million in low- and middle-income 
countries. That total represents 65% of the global target of 15 million people set for 2015 (WHO, 
2013). 
Currently, there are more than twenty ARV drugs available, distributed by seven classes, according 
to their mechanism of action in the several steps of the HIV-life cycle (Fig 1.1). These drugs are used 
in combination of three, two of which are nucleoside or nucleotide reverse transcriptase inhibitors 
(NtRTIs) plus one of the following options: a non-nucleoside reverse transcriptase inhibitor (NNRTI), 
one protease inhibitor (PI) boosted with ritonavir, or one integrase inhibitor (INI). Occasionally, these 
regimens could be altered if there is any presence of virological failure, side effects, pregnancy and 
co-infections (EACS, 2011; DGS, 2012). The choice of cART and the optimal time for its start for each 
patient should be in accordance with several parameters, such as clinical manifestations, the number 
of CD4 lymphocytes (<350 cell/mm
3
), the viral load and the presence of co-morbidities. 
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Figure 1.1 Schematic representation of the HIV-life cycle main steps and the targets 
of the several classes of antiretroviral drugs (Chen et al., 2007). Mechanism of 
action, through the different phases of HIV-life cycle, of the different antiretroviral drugs 
classes: nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse 
transcriptase inhibitors (NtRTIs), non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), protease inhibitors (PI), fusion inhibitors (FI), co-receptors inhibitors (CRIs) and 
integrase inhibitors (INIs) (De Clercq, 2009). 
 
The ARV drugs are a very dynamic therapeutic group since, drug availability, drug combination and 
also the criteria for the beginning and managing of cART has widely varied throughout the last two 
decades. Currently, the national guidelines state that the first-line cART should include a first 
generation NNRTI, nevirapine (NVP) or efavirenz (EFV) (DGS, 2012). Successful cART is associated 
with dramatic decreases in AIDS-defining conditions (Thompson et al., 2010) and an increase in 
lifespan and quality of life of HIV-infected patients. Nevertheless, this clinical condition still faces 
several obstacles due to its chronic treatment, such as the adherence to a daily administration 
schedule, the loss of therapeutic efficacy and the drug-associated toxicity (Caixas et al., 2012). 
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Increased evidence supports the association between CVD and cART in HIV-infected patients. The 
Data Collection on Anti-HIV Drugs (DAD) study showed that overall, cART was associated with a 26% 
relative increase in the rate of myocardial infarction (MI), per year of exposure during the first four to 
six years of use (The DAD Study Group, 2003). In HIV-infected patients, lipid abnormalities are very 
common (Grunfeld et al., 1992), which as consequence, can lead to further development of CVD. 
Before treatment, HIV-infection results in substantial decreases in serum total cholesterol (TC), 
high-density lipoprotein (HDL), low-density lipoprotein (LDL) levels (Grunfeld et al., 1992; Riddler et 
al., 2003), and an increase in triglycerides (TG) levels (Fernández-Miranda et al., 1998). Though not 
always is possible to see hypertriglyceridemia in early stages of the infection (Grunfeld et al., 1992; 
Zangerle et al., 1994), low levels of HDL are present in all its stages (Grunfeld et al., 1992; Zangerle et 
al., 1994; Fernández-Miranda et al., 1998). The Multicenter AIDS Cohort Study (MACS) is one of the 
best reports that show that the reduction of HDL and LDL levels is associated with the infection 
(Riddler et al., 2003), as it is the only study that has access to the patient’s lipidic profile before the 
infection, post-infection without cART and after cART initiation. The first two stages were 
characterized by low levels of TC (-30 mg/dL), LDL (-22 mg/dL) and HDL (-12 mg/dL). Subsequent 
cART initiation was associated with increases in TG, TC and LDL but little change in HDL levels 
(Riddler et al., 2003). 
 
Both controlled and uncontrolled HIV-infection are associated with the risk of developing CVD. In 
treated HIV-infected patients, several metabolic complications have been associated with cART 
(Grinspoon and Carr, 2005), including dyslipidemia, insulin resistance and overt diabetes mellitus, all 
well-known risk factors for the development of CVD (Carr et al., 1999; Vergis et al., 2001; The DAD 
Study Group, 2003). 
The introduction of cART has improved both morbidity and mortality rates of HIV-infected patients 
(Palella Jr et al., 1998). Hence, it was expected that the successful control of HIV-infection would also 
reduce the risk of coronary artery disease (CAD) associated with the condition. However, the reported 
data suggests the opposite: despite treatment or possibly because of it, HIV-infection is associated 
with an increased risk of development of atherosclerosis (Hsue et al., 2004) and at least a threefold of 
the risk of CAD (Hsue et al., 2004; de Saint Martin et al., 2006). Moreover, both MI (Guaraldi et al., 
2010) and asymptomatic ischaemic disease (Calza et al., 2005) are also common conditions in 
HIV-infected patients. As so, cardiovascular complications are rapidly becoming one of the prevalent 
causes of morbidity and mortality in HIV-infected patients (Varriale et al., 2004), and though the 
relative contribution of HIV-infection itself and adverse effects of cART is not quite clear, two 
consistent trends have emerged. Firstly, the risk of CVD is higher in untreated than treated HIV 
infection, probably because inflammation is increased on the first case (Kuller et al., 2008). Secondly, 
some ARVs have direct effects that can potentiate the development of CVD. For instance, prolonged 
exposure to PIs is associated with hyperlipidaemia, insulin resistance and a higher rate of CVD events 
(The DAD Study Group, 2007). Moreover, abacavir (ABC), a commonly used nucleoside reverse 
transcriptase inhibitor (NRTI), seems to increase the risk of heart disease (Sabin et al., 2008), perhaps 
because of its pro-inflammatory effect induced by toxic metabolites formation (Grilo et al., 2013).  
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Nevertheless, HIV-infection per se is connected with dyslipidaemia and, particularly in advanced 
states, it has been shown to be an independent risk factor for adverse lipid parameters (El-Sadr et al., 
2005; Batuca et al., 2012). 
 
 
1.2 High-density lipoprotein in HIV-infection: the influence of combined 
antiretroviral therapy 
 
Among the several factors influencing CVD, HDL is the most powerful independent predictor. The 
HDL protective effects have first been attributed to the ability to promote cellular cholesterol efflux from 
peripheral cells to the liver for excretion, a process known as reverse cholesterol transport (RCT) 
(Précourt et al., 2011), which is essential for preventing foam cell formation and consequent 
atherosclerosis (Tohyama et al., 2009). HDL is also involved in the inhibition of oxidation, 
inflammation, activation of the endothelium and coagulation or platelet aggregation (van Leuven et al., 
2007). 
Additionally, HDL has also several other features that able it to be used for the assessment of the 
risk for developing CVD. For instance, on a methodological view, HDL can be an effective biomarker 
due to its easy quantification. Moreover, from an epidemiologic perspective, this lipoprotein has also 
been shown to be crucial for the development of many cardiovascular events in the non-HIV 
population. Large prospective studies such as the Framingham Heart study, the Prospective 
Cardiovascular Münster (PROCAM) study, the Helsinki Heart study and the Lipid Research Clinics 
Prevalence Mortality study have shown that the risk of CAD is reduced by 2-5% for every 0.025 
mmol/L increase in plasma HDL levels (Abbott et al., 1988; Wilson et al., 1988; Frick et al., 1990; 
Jacobs et al., 1990; Assmann and Schulte, 1992; Assmann, 2001; Clotet et al., 2003). From a 
pharmacological point of view, till this time, few drugs have the capacity to increase HDL levels, all of 
them showing practically no clinical benefits, as the increase in HDL concentration is really low 
(Birjmohun et al., 2005; Filippatos and Elisaf, 2013). All the attempts to develop new drugs with HDL 
boosting effect have failed. Intensive efforts are in progress to develop new drugs that not only 
increases HDL quantity but also its quality (Tall et al., 2007; Filippatos and Elisaf, 2013). 
In HIV-patients, HDL metabolism is affected (Shor-Posner et al., 1993; The DAD Study Group, 
2007). However, in contrast to the atherogenic lipoprotein profile observed in patients treated with 
other HIV drugs such as PIs (Riddler et al., 2003), several studies have demonstrated that treatment 
with NNRTIs such as NVP and EFV, increase plasma levels of HDL cholesterol by up 49% (van der 
Valk et al., 2001; Clotet et al., 2003; Tebas et al., 2004; van Leth et al., 2004; Fisac et al., 2005; 
Young et al., 2005; Pereira et al., 2006), through an unknown mechanism. Moreover, NVP increases 
HDL and improves TC/HDL ratio apparently more than does EFV (van Leth et al., 2004; Fisac et al., 
2005). NVP-containing cART may therefore contribute to reducing the risk of CVD in patients with 
HIV-infection, as well as it has been shown to have a protective role in pre-diabetic patients, behaving 
as a CVD-friendly drug (Srivanich et al., 2010). 
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Nowadays, the information given by HDL quantity has to be complemented with quality 
assessment (Tall et al., 2007; Filippatos and Elisaf, 2013). In this context, the enzyme paraoxonase-1 
(PON1) has been implicated to play a pivotal role in the antioxidant protective functions of HDL, as it is 
found closely bound to this lipoprotein particle (Lusis, 2000; Gaidukov et al., 2006). 
 
 
1.3 The paraoxonase family in HIV-infection. The effect of combined 
antiretroviral therapy on PON1 activities 
 
The PON enzyme family comprises three members, namely PON1, PON2 and PON3, that exhibits 
antioxidative properties mainly in the blood circulation. Their corresponding genes appears to have 
arisen from a duplication event of a common evolutionary ancestral, as they share considerable 
structural homology and are located adjacent to each other on chromosome 7q21-22 (Primo-Parmo et 
al., 1996). 
The three PON enzymes have different cell and tissues distributions, as well as different regulatory 
mechanisms. In the human body, PON1 and PON3 are found associated to HDL in circulation 
(Furlong, 2008). Regarding PON2, it is an intracellular enzyme, which is not detectable in serum, but 
is expressed in many tissues including brain, liver, kidney and testis (Ng et al., 2001). 
The different tissue distributions suggest distinct physiological roles for each of them, though they 
remain largely unknown (Draganov, 2007). Nevertheless, all three enzymes are able to reduce LDL 
oxidation (Aviram and Rosenblat, 2004). Moreover, PON2 is also able to reduce cellular oxidative 
stress and prevents apoptosis in vascular endothelial cells (Horke et al., 2007). Among the three 
enzymes, PON1 is the best well known and characterized family member, and much of our 
understanding of PON enzymes is derived from the studies involving PON1 proteins. 
In 1946, Abraham Mazur, who reported the presence of an enzyme in animal tissue able to 
hydrolyze organophosphate compounds (Mazur, 1946), led to the initial identification of PON1 
(Aldridge, 1953a, b). PON1 is a calcium-dependent serum A-esterase enzyme, which protects LDL 
from oxidative modification by hydrolyzing lipid peroxides, thus exerting antioxidant and 
antiatherogenic effects (Mackness et al., 1993). This glycoprotein of 354 amino acids, with a molecular 
mass of 43-45 kDa, is expressed in a variety of tissues (Marsillach et al., 2008), but it seems probably 
that the liver is the main source of serum PON1. This organ is reported to have the highest PON1 
gene expression and is also where a great part of HDL is synthesized and secreted into the circulation 
(Camps et al., 2009). 
In 1991, Mackness and co-authors did the first approximation for the identification of the 
physiological role of PON1, by showing that the enzyme prevents the generation of lipoperoxides 
during the process of LDL oxidation (Mackness et al., 1991a). Subsequent studies reached the 
conclusion that PON1 protects LDL and HDL from lipid peroxidation by degrading oxidized cholesteryl 
esters and oxidized phospholipids contained in oxidized lipoproteins (Mackness et al., 1993; Navab et 
al., 1996; Aviram et al., 1999). On the other hand, PON1 is inactivated by oxidized lipids, as shown by 
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Aviram and co-authors in an in vitro incubation of PON1 with oxidized palmitoyl arachidonoyl 
phosphatidylcholine, lysophosphatidylcholine and oxidized cholesteryl arachidonate (Aviram et al., 
1999). PON1 was also shown to be able to hydrolyze hydrogen peroxide, a potentially important 
oxidative stress mediator in atherosclerosis (Aviram et al., 1998). The effects of PON1 overexpression 
were also investigated in mice. Oda and co-authors (2002) generated a mouse model of a 5-fold 
increase in PON1 expression specifically in the liver. They found that PON1 was redistributed to HDL 
vehicles in the circulation. However, increased PON1 content in HDL did not alter HDL composition or 
properties, except that they were more protected from lipid peroxidation (Oda et al., 2002). 
Numerous factors are known to influence PON1 status (Fig 1.2), including diet and life style habits 
(Deakin and James, 2004; Aviram et al., 2005; Costa et al., 2005b). Also, PON1 polymorphisms and 
its association with lipid metabolism, CVD and ischemic stroke have been documented in a 
considerable number of studies (McElveen et al., 1986; Mackness et al., 1991b; Garin et al., 1997; 
Voetsch et al., 2002). Epidemiological and molecular studies have identified that there are two major 
common functional genetic polymorphisms in the coding region of the PON1 gene due to glutamine or 
arginine at position 192 (Q192R) and leucine or methionine at position 55 (L55M) (Adkins et al., 1993; 
Humbert et al., 1993). The L55M polymorphism is located in the N-terminal side of PON1 gene, which 
plays a role in the binding of PON1 to HDL. Moreover, it also affects the enzyme concentration 
(Adkins et al., 1993) with the M allele causing a decrease in protein stability (Leviev et al., 2001). On 
the other hand, the Q192R polymorphism does not affect PON1 protein concentration (Leviev and 
James, 2000), although it is responsible for a striking substrate specific difference in the hydrolytic 
activities of the enzyme (Adkins et al., 1993; Humbert et al., 1993; Leviev et al., 2001), especially in 
what regards the Q allele (Davies et al., 1996; Mutch et al., 2007). Furthermore, four additional 
polymorphisms in the promoter region of the PON1 gene has also been reported, namely C-107T, 
A-162G, G-824A and G-907C. These polymorphisms are reported to affect the expression and thus 
the serum concentration of the enzyme (Leviev and James, 2000). The C-107T polymorphism has 
been the most important genetic determinant of PON levels (Brophy et al., 2001; Deakin et al., 2003), 
influencing the gene expression, with the T allele reducing PON1 levels. This polymorphism 
contributes around 22-25% of variation in PON1 expression in caucasian adults (Leviev and James, 
2000; Brophy et al., 2001). However, PON1 allele frequencies show great variations between different 
populations (Rojas-Garcia et al., 2005) and ethnic groups (Brophy et al., 2001; Ginsberg et al., 2009). 
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Figure 1.2 Biological effects of PON1 and its modulation (Macharia et al., 2012). 
(PON1 - paraoxonase-1; Apo A1 – Apolipoprotein A-1; HDL – high-density lipoprotein) 
 
The PON1 enzyme is considered as a human body endogenous free-radical scavenging system 
and has three main activities identified that could possibly explain its antioxidant and anti-inflammatory 
potential, which are paraoxonase (POase), arylesterase (AREase) and lactonase (LACase) activities. 
 
Paraoxonase Activity 
 
The enzyme was firstly found to have POase activity, reflecting its ability to catalyze the hydrolysis 
of paraoxon, an insecticide that gave rise to the family name, hence protecting against xenobiotic 
toxicity (Costa et al., 2005a). The POase activity is not shared by the three enzymes of the PON 
family, as it is only confined to PON1. 
Several reports using paraoxon as substrate demonstrated that there is a high inter-individual 
variability in PON1 POase activity (Humbert et al., 1993), considering part of this variability due to the 
polymorphisms found for the PON1 gene. Regarding the Q192R polymorphism, the Q allele has been 
reported to have lower POase activity than the R allele (Humbert et al., 1993; Davies et al., 1996; 
Mackness et al., 1997; Li et al., 2000). For the L55M polymorphism, the L allele is correlated with 
higher POase activity and mRNA levels than the M allele (Leviev et al., 1997; Li et al., 2000). 
Moreover, PON1 C-107T polymorphism also has influence on the POase activity. For instance, the 
homozygotes for the T allele have, on average, 33-45 % lower POase activity as adults (Leviev and 
James, 2000; Brophy et al., 2001) and 63 % lower as neonates (Chen et al., 2003), relatively to the C 
homozygotes. Overall, genetic factors, including polymorphisms, were found to explain more than 
60 % of phenotypic variance in PON1 POase activity, while demographic environmental factors 
accounted for only 1-6 % of changes and metabolic covariates for 4-19 % (Rainwater et al., 2009). 
The ability of PON1 to hydrolyze paraoxon was employed as a method to measure PON1 activity in 
several species and tissues. However, despite most of the studies exploring the role of PON1 in 
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disease used the POase activity as a biomarker for the enzyme status (Pereira et al., 2009; Soyoral et 
al., 2011), this activity does not reflect the real physiological role of PON1. Thus, it is critical to start 
looking at its remaining activities, AREase and LACase, which have been proved to be more 
physiological (Rosenblat et al., 2006). 
 
Arylesterase Activity 
 
The detoxification of lipid peroxides by PON1 is possible via its AREase activity, being phenyl 
acetate one of its best substrates. Due to this feature, this activity is thought to be the one which best 
reflects the antioxidant capacity of PON1 (Rosenblat et al., 2006). Hence, PON1 AREase activity 
seems to be involved on the reduction of the magnitude of LDL oxidation. It was found that 
components of oxidized LDL (ox-LDL) displayed the potency to strongly inactivate the activity. 
However, the presence of antioxidants, such as flavonoids, quercetin and glabridin during LDL 
oxidation, attenuated the loss of PON1 AREase activity (Aviram et al., 1999). On the other hand, the 
activity declined rapidly in HDL following treatment with 3-morpholinosydnonimie, which generates 
peroxynitrite, a powerful oxidant (Ahmed et al., 2001). PON2 does not have this activity and although 
PON3 also has it, it is very limited. 
Regarding PON1 polymorphisms influence in the enzyme AREase activity, there has been some 
controversy. Initially, it was proposed that, in contrast with the POase activity, the measurement of the 
AREase activity of PON1 was not influenced by genetic polymorphisms (Eckerson et al., 1983). 
Nevertheless, in 2001, Brophy and co-authors reported that the highest AREase activity was reported 
in individuals with the 192QQ genotype (Brophy et al., 2001). Additionally, in a more recent study by 
Rainwater and co-authors (2009), the highest AREase activity was found in 192RR and 55LL 
individuals (Rainwater et al., 2009). 
 
Lactonase Activity 
 
PON1 LACase activity was the latest to be discovered and protects against homocysteine 
thiolactone (HcyTL) toxicity (Jakubowski, 2000). Moreover, this activity is also involved in the 
metabolism of certain drugs, including the activation of the aquinolone antibiotic NM394, by the 
hydrolysis of the unsaturated cyclic carbonate prodrug prulifloxacin (Tougou et al., 1998). The LACase 
activity of PON1 has also been used in the development of locally acting glucocorticoid drugs, which 
undergo rapid hydrolysis and inactivation when they reach the circulation (Biggadike et al., 2000). 
More recently, PON1 LACase activity has been linked to the efficacy of clopidogrel (Camps et al., 
2011), an antithrombotic drug used to prevent CAD. The prevailing notion is that the hydrolytic activity 
towards lactones is the native activity of PON1 – a view supported by structure-activity studies 
indicating that lactones are the preferred substrate of PON1 (Harel et al., 2004). Moreover, as the 
enzyme play a role in anti-inflammatory and antioxidant response, many oxidized metabolites of 
polyunsaturated fatty acids are structurally similar to lactones (Draganov et al., 2005). The LACase 
activity is believed to have been conserved throughout the evolution of the enzyme, since it is shared 
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by all three members of the PON family. In fact, the term lactonase has been suggested as more 
fitting for the PON family as PON2 and PON3 lack any notable POase activity (Ng et al., 2005). 
Although The PON1 natural-substrates are uncertain, HcyTL is hydrolyzed to homocysteine (Hcy) 
by PON1 LACase activity (Mackness et al., 1996; Draganov, 2007), and is a well-known risk factor for 
the development of CVD (Jakubowski, 2000; Clarke et al., 2007). HcyTL is formed in all cell types, 
resulting from an error-editing of the met-tRNA synthetase when there is excess of Hcy. The 
interaction of HcyTL with proteins leads to protein homocysteinylation and loss of function 
(Jakubowski et al., 2000). Therefore, detoxification of HcyTL is crucial, which in turn, is possible by the 
LACase activity of PON1 (Domagala et al., 2006), contributing to its cardioprotective role. Regarding 
the polymorphisms modulation, the highest LACase activity was detected in 192QQ and also in 55LL 
individuals (Brophy et al., 2001; Rainwater et al., 2009). 
 
 
Concerning HIV-infection, it is likely that PON1 contributes to the beneficial effects of higher HDL 
levels in HIV-infected patients. However, few or no data is available about the influence of 
HIV-infection and cART on PON1 activities, which can further reflect the quality of HDL on these 
patients. Nevertheless, the majority of the studies reporting PON1 activities in HIV-infected patients 
concern the POase activity. Usually, the patients have lower serum PON1 POase activity and higher 
PON1 concentration than the general population, and the activity is inversely correlated with the 
concentration of ox-LDL (Parra et al., 2007). Both activity and concentration is thought to be 
influenced by HIV-infection, the alterations in HDL composition and the immunological state of the 
patients. Furthermore, a positive association was found between serum PON1 concentration and 
active viral replication (Parra et al., 2007), which further suggests that PON1 could play a beneficial 
role in protecting patients from HIV-infection. This activity was also found to be significantly higher in 
patients treated with EFV than in patients without cART (naïve) (Pereira et al., 2006). Another study 
through the POase activity reported that the enzyme appeared to be a marker for metabolic syndrome 
in HIV-population (Bobin-Dubigeon et al., 2013). For the LACase activity, no differences were found 
between healthy and HIV-infected subjects regardless of cART use (Djeghader et al., 2012). 
 
 
1.4 Nevirapine two-faces: an high-density lipoprotein booster VS an 
hepatotoxic drug 
 
Several studies reported that NVP raises HDL levels, resulting in an improvement of the 
atherogenic index of the HIV-infected patients (van der Valk et al., 2001; van Leth et al., 2004). The 
drug has been associated to an HDL increase up to 49%, which represents a more pronounced effect 
than the obtained with the currently available HDL-raising drugs, and is thought to be due to the 
stimulation of the apolipoprotein A-1 (Apo A-1) production (van Leth et al., 2004; Sankatsing et al., 
2007; Franssen et al., 2009). 
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NVP was the first NNRTI approved by the US Food and Drug Administration (FDA), in 1996, for the 
treatment of HIV type-1 infection, as part of cART (FDA, 1996). The drug acts by non-competitive 
inhibition of HIV-1 reverse transcriptase (Sweetman, 2008), and still is the most prescribed drug of its 
class, partly due to its low cost (Ades et al., 2000; Lockman et al., 2007). Furthermore, NVP has many 
features that can make it prone for its use in several conditions. The favorable metabolic profile 
conferred by the drug (Ruiz et al., 2001; Clotet et al., 2003; Srivanich et al., 2010) turns it suitable for 
use in patients with diabetes, dyslipidemia or metabolic syndrome comorbidities. Moreover, the low 
incidence of adverse drug reactions in the central nervous system (Medrano et al., 2008), in 
opposition to the other first-line NNRTI EFV, also allows its use in the context of psychiatric disorders 
or addiction to narcotic drugs. NVP is also highly efficient on the prevention of mother-to-child 
transmission of the HIV-1 infection, with the drug being commonly prescribed to pregnant women and 
their children (Ades et al., 2000; Medrano et al., 2008; Sweetman, 2008). Several studies have shown 
that NVP-based cART is capable of increasing plasma levels of HDL and that this effect is greater 
than the one expected from simply suppressing HIV alone. Hence, a NVP-based regimen could 
potentially reduce the cardiovascular risk for HIV-infected patients (van der Valk et al., 2001; van Leth 
et al., 2004; Fisac et al., 2005). 
While NVP is being monitored safely for long-term use in patients who are able to tolerate the initial 
regimen, the FDA has issued a black box warning to include information on hepatotoxicity associated 
with long-term use, and recommends against starting female patients on NVP if their CD4
+
 count is 
>250 cells/µL and for male patients if their CD4
+
 cell count is >400 cells/µL (Clotet, 2008). 
Hence, the use of NVP has been associated with adverse toxicity reactions such as idiosyncratic 
hepatotoxicity and cutaneous hypersensitivity (Taiwo, 2006; De Lazzari et al., 2008; Medrano et al., 
2008). These concerns arose following case reports of liver failure in individuals on post-exposure 
prophylaxis (Johnson and Baraboutis, 2000) and in asymptomatic HIV-infected patients with 
well-preserved immunity, administered NVP-containing first line cART (Cattelan et al., 1999; Stern et 
al., 2003). Clinically, most patients on NVP present with erythematous rashes often accompanied by 
fever, and in some cases with internal organ involvement (Pollard et al., 1998). Nevertheless, a two 
week period of low dose treatment reduces the risk of rash (Montaner et al., 2003), which is currently 
being applied as guideline. 
However the mechanism that underlays this drug toxicity is still uncertain, several in vitro (Antunes 
et al., 2008; Antunes et al., 2010a; Antunes et al., 2010b), in animal models (Shenton et al., 2003; 
Chen et al., 2008) and in man (Caixas et al., 2012; Marinho et al., 2013; Meng et al., 2013; Sharma et 
al., 2013) approaches have suggested that the bioactivation of the phase-I NVP metabolite 
12-hydroxy-Nevirapine (12-OH-NVP), to reactive electrophiles, such as 12-sulfoxi-nevirapine 
(12-sulfoxy-NVP) is involved (Antunes et al., 2008; Chen et al., 2008; Antunes et al., 2010a; Antunes 
et al., 2010b; Caixas et al., 2012; Pereira et al., 2012). 
Nevertheless, the less atherogenic lipid profile conferred by NVP could potentially make it a 
suitable component in first-line regimens for HIV-positive patients with multiple risk factors for 
cardiovascular events (van Leth et al., 2004). Moreover, in second-line regimens the PI component 
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could be substituted for NVP in order to improve PI-initiated lipid abnormalities (Gil et al., 2004; Fisac 
et al., 2005). 
 
 
1.5 Objectives 
 
What is known? 
 
1. CVD is currently the number one cause of mortality and morbidity in HIV-infected patients. 
2. Low HDL levels are considered the most negative predictor of CVD. 
3. NVP surely works as an HDL-modulator and its positive effect on HDL is greater than the 
available drugs with HDL booster properties. 
4. Beyond HDL quantity, its quality is also relevant. 
5. PON1 enzyme is responsible for the HDL antioxidant function. 
6. PON1 is an enzyme synthesized by the liver and has three main functions: paraoxonase, 
arylesterase and lactonase. 
7. NVP upon biotransformation gives rise to several phase-I metabolites. 
8. The bioactivation of the phase-I metabolite 12-OH-NVP is a plausible mechanism underlying 
NVP hepatotoxicity. 
 
What is needed to know? 
 
1. What is the individual contribution of NVP and each one of its phase-I metabolites on PON1 
activities? 
2. Is PON1 a protective player against NVP toxicity? 
 
Working hypothesis: 
 
NVP is known to increase HDL levels (Sankatsing et al., 2007), and can be considered a good 
alternative against the development of CVD or even in patients already with the condition. The current 
work aims at explore this HDL-booster effect provided by NVP as well as analyzing its quality, where 
PON1 is a major player.  
However, NVP is associated with hepatotoxicity and skin rash (Yuan et al., 2011), and the 
bioactivation of its phase-I metabolite 12-OH-NVP, through the formation of protein adducts, is a 
plausible mechanism underlying this toxicity (Caixas et al., 2012) (Fig. 1.3). These toxic effects can be 
potentiated due to the decrease in the antioxidant defenses presented in HIV-infection. As PON1 is an 
antioxidant enzyme, we hypothesize that may be it could also have a role on this context. 
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Figure 1.3 Nevirapine biotransformation, disposition and proposed bioactivation 
pathways (Marinho et al., 2013) (adapted). NVP is metabolized into its phase-I metabolites, 
by several isoforms of cytochrome P450 (CYP450), which are 2-hydroxy-nevirapine 
(2-OH-NVP), 3-hydroxy-nevirapine (3-OH-NVP), 8-hydroxy-nevirapine (8-OH-NVP) and 
12-OH-NVP. This last metabolite is further oxidized by CYP450, giving rise to 
4-carboxy-nevirapine (4-COOH-NVP). The UDP-glucoronosyltranferase (UGT) also represents 
a major pathway of NVP elimination. The bioactivation of 12-OH-NVP by SULTs can generate 
12-sulfoxi-nevirapine (12-sulfoxy-NVP), which is a reactive metabolite that can bind to proteins 
and deoxyribonucleic acid (DNA). 
 
PON1 is part of the endogenous detoxification system (Fig 1.4). On one hand the enzyme is 
capable of detoxifying several endogenous toxic compounds (e.g. oxidized lipids and HcyTL) that can 
further lead to toxicity. On the other hand, PON1 enzyme can also contribute to the production of 
glutathione (GSH), another known antioxidant. As so, our work hypothesizes is that PON1 could have 
a protective role against the toxicity inherited to the use of NVP. 
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Figure 1.4 Work hypothesis. (PON1 - paraoxonase-1; HcyTL - homocysteine thiolactone; 
Hcy - homocysteine;; Cys – cysteine; Cys-Gly – cysteine-glycine; GSH – glutathione) 
 
On this regard, the present study is aimed at (Fig. 1.5): 
 
1. Develop and validate new methods for the quantification of the AREase and LACase activities, 
suitable for application in human blood. 
2. Quantify the AREase, LACase and POase activities in HIV-infected patients under NVP-containing 
cART. 
3. To explore the effect of chronic exposure of NVP and its phase-I metabolites on the three PON1 
activities. 
 
It is generally expected to give new insights on the mechanisms underlying NVP effects on 
HDL properties and to also give evidence for a plausible protective role of PON1 in the NVP-toxicity as 
well as give support to a rational prescription of lipid friendly cART in HIV-infected patients with or at 
increased of CVD development. 
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Development and validation of methods 
for the assessment of PON1 AREase and 
LACase activities. 
Quantification of the PON1 activities in 
serum samples of HIV-infected patients 
under NVP-containing cART 
Quantification of NVP and its phase I 
metabolites in plasma samples of  
HIV-infected patients 
a) Effect of NVP and its phase-I metabolites on PON1 activities 
b) Protective role of PON1 on NVP toxicity 
Figure 1.5 Graphic summary of the work plan. (PON – paraoxonase-1; AREase – arylesterase; 
LACase – lactonase; HIV – human immunodeficiency virus; NVP – nevirapine; cART – combined 
antiretroviral therapy; 2-OH-NVP – 2-hydroxy-nevirapine; 3-OH-NVP – 3-hydroxy-nevirapine; 
8-OH-NVP – 8-hydroxy-nevirapine; 12-OH-NVP – 12-hydroxy-nevirapine) 
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2.  Materials and Methods 
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2.1 Inclusion of patients, clinical data gathering and blood sampling 
 
A group of healthy volunteers were included for the definition in method validation of the blood 
sampling conditions for the PON1 activities assessment. Blood samples were collected by 
venipuncture, at the Centro Hospitalar de Lisboa Central, EPE. 
The current work was conducted in accordance with the Declaration of Helsinki. The study protocol 
received prior approval from the Ethics Committees of Centro Hospitalar de Lisboa Central, EPE 
(process number 32-CHLC) and Hospital Prof. Doutor Fernando Fonseca, EPE (process number CA 
21/2011), and was also approved by the National Committees for Data Protection (process number 
6567/2009). All patients gave their written informed consent and adherence was controlled by the 
clinicians. All patients were adults with documented HIV-infection, who had received continuous 
treatment with NVP-containing cART regimens (400 mg once daily) for more than 1 month, regardless 
of the past therapeutic history. Exclusion criteria were defined as being less than 18 years of age, 
having AIDS-defining conditions, and compliance issues. The following clinical data were gathered for 
each patient: age, sex, ethnicity, weight and height, time on NVP, viral load, CD4 T-cells count, and 
lipid parameters (e.g. HDL, LDL, TG and TC). Blood samples were collected by venipuncture.  
 
 
2.2 PON1 activities assessment 
2.2.1 Arylesterase activity of PON1 
 
In order to assess PON1 AREase activity, a new method was developed and validated. 
 
i. Rational 
 
Although being considered a non-physiological activity, the measurement of the POase activity of 
PON1 enzyme using paraoxon as substrate has been the most widely used standardized method for 
the assessment of its status (Pereira et al., 2009; Soyoral et al., 2011). Therefore, the study of the 
AREase activity of PON1, which best reflects its antioxidative role, can potentially give additional 
information. 
Despite the methods already available for this purpose (Beltowski et al., 2002; Naderi et al., 2011), 
they do not fulfill our aims of easy application in clinical setting. The rational for the method developed 
herein is taking advantage of the acetic acid production by the hydrolysis of phenyl acetate, a 
substrate of the AREase activity of PON1 (Fig 2.1). The acetic acid formation can be monitored by the 
color variation of the titration with phenol red reagent. Briefly, a molecule of phenyl acetate is 
hydrolyzed into phenol and acetic acid. Hence, the acetic acid is produced in stoichiometric amounts 
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to the substrate hydrolysis. This reaction can be monitored spectrophotometrically, at 405 nm, by the 
color change of the phenol red reagent. 
 
 
Figure 2.1 Method rational: hydrolysis of phenyl acetate by paraoxonase-1 and its 
monitoring for the assessment of the arylesterase activity. (AREase – Arylesterase; 
PON1 - paraoxonase-1) 
 
ii. Standards preparation for the calibration curve 
Stock solutions 
The stock solutions were prepared by adding the appropriate amount of acetic acid (M&B 
Laboratory Reagents) and phenol (Fluka) in freshly prepared HEPES (Roth) buffer (2.0 mM, at pH 
8.0), containing CaCl2 (BDH Chemicals Ltd Pool England) (1.0 mM) and albumin from bovine serum 
(BSA) (Roth) (0.005%). Ideally, these solutions should be used right after its preparation and should 
be prepared in tubes covered in aluminum, since phenol is a photoreactive compound. 
 
Standards preparation 
For the preparation of the standards, the stock solutions were diluted in physiological serum in 
order to obtain six standards. Furthermore, a standard only with physiological serum and HEPES 
buffer (blank sample) was also prepared in order to correct the non-enzymatic hydrolysis of phenyl 
acetate. 
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iii. Standard operating procedure 
 
The AREase activity was obtained by measuring the extent of the hydrolysis of phenyl acetate 
using a spectrophotometric method adapted for a 96-well microplate. Serum or plasma samples were 
diluted in the proportion of 1:5 in physiological serum and 10 µL were added per well. The samples 
and the previous prepared standards were incubated at 37 °C, during 10 minutes. Subsequently, 
190 µL of freshly prepared HEPES buffer (2.0 mM, at pH 8.0) containing CaCl2 (1.0 mM), BSA 
(0.005%), phenol red (Fluka) (106 µM) and 5.0 mM phenyl acetate (Fluka) (5.0 mM) were added to 
each well. The absorbance at 405 nm was measured on a microplate reader (Biotrack II plate reader, 
Amersham Biosciences). The activity was directly obtained from the calibration curve and expressed 
as kU/L, defined as the amount of enzyme producing 1 mM of acetic acid per minute. All 
samples/standards were analyzed in triplicate. 
 
iv. Method validation 
 
The validation criteria were defined according to guidebooks, regarding the validation of 
bioanalytical methods (Shah et al., 1992; González and Herrador, 2007; EMA, 2011). For all validation 
purposes, each sample was analyzed in triplicate. 
 
Linearity 
Three calibration curves were prepared from different stock solutions and using six standards 
within the concentration range: 5.50 mM (lower limit of quantification, LLOQ) to 26.21 mM (higher limit 
of quantification, HLOQ). The calibration curves were constructed to explore the linearity of the 
method. Also, the slopes and Y-intercept (Y0) of the curves where compared in order to access 
reproducibility. 
 
Lower limit of quantification 
In order to validate the LLOQ, six samples with a concentration of 5.50 mM were analyzed for the 
accuracy and the intra-assay and the inter-assay precisions. 
 
Accuracy 
To study the accuracy of the method, six samples from the LLOQ and the HLOQ as well as 2 
quality control samples (QC1 and QC2) in between the concentration range (12.58 mM and 
16.78 mM) were analyzed. The accuracy was calculated according with the equation (1) and 
expressed in percentage (%) 
 
 Accuracy (%) = 
___________________ 
obtained concentration 
exact concentration 
x 100                             (1) 
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Precision 
Intra-assay precision 
The intra-assay precision was evaluated by analyzing six aliquots of the LLOQ, QC1, QC2 and 
HLOQ. These aliquots were analyzed on the same run. 
The intra-assay precision was obtained by subtracting the variation coefficients (CV) of the 
analyzed aliquots, according with the equation (2). The calculation of the intra-assay precision was 
performed assuming that its value would ideally be 100%. Samples obtained from a healthy volunteer 
were also analyzed. 
 
 
Inter-assay precision 
For the study of this parameter, the same samples described in the previous sub-section were 
analyzed, albeit these analyses were performed in different runs. The inter-assay precision was 
calculated using the equation (3). Samples obtained from a healthy volunteer were also analyzed. 
 
 
 
2.2.2 Lactonase activity of PON1 
 
In the subsequent sections it is described the steps used to develop and validate a method to 
assess PON1 LACase activity. 
 
i. Rational 
 
The study of the LACase activity of PON1 also gives additional and relevant information than only 
using the POase activity for the assessment of PON1 status. Moreover, as the LACase activity is 
thought to be the primary activity of PON1, the interest is increased (Harel et al., 2004). The 
development of new techniques for the quantification of this activity is of crucial importance, as this is 
the activity known to detoxify innumerous toxic lactones, including HcyTL, a major player in CVD 
(Jakubowski, 2000). 
Several methods have already been proposed for the assessment of the LACase activity of PON1 
(Billecke et al., 2000; Gaidukov and Tawfik, 2005; Rock et al., 2008), though all of them have inherited 
disadvantages in what concerns its clinical application. The method herein proposed is based on the 
production of 3-(o-hydroxyphenyl) proprionic acid (o-HPPA) when the lactone, dihydrocoumarin 
(DHC), is hydrolyzed by PON1 LACase activity (Fig. 2.2). This reaction can be monitored by the color 
change from red to yellow of the titration with phenol red reagent. Briefly, a molecule of DHC is 
Intra-assay precision (%) = 100 - CV                                      (2) 
Inter-assay precision (%) = 100 – Inter-assay CV                  (3) 
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hydrolyzed into a molecule of o-HPPA. Hence, the acid is produced in stoichiometric amounts to the 
amount of substrate hydrolysis. This reaction can be monitored spectrophotometrically, at 405 nm, by 
the color change of the phenol red reagent. 
 
 
Figure 2.2 Method rational: hydrolysis of dihydrocoumarin by paraoxonase-1 and 
its monitoring for the assessment of the lactonase activity. (LACase – lactonase; 
PON1 - paraoxonase-1) 
 
ii. Standards preparation for the calibration curve 
Stock solutions 
The stock solutions were prepared, by adding the appropriate amount of o-HPPA (Sigma-Aldrich) 
in freshly prepared HEPES buffer (2.0 mM, pH 8.0), containing CaCl2 (1.0 mM) and BSA (0.005%). 
 
Standards preparation 
The standards were prepared with the same procedure used for the method for the AREase activity 
assessment. 
 
iii. Standards operating procedure 
 
The LACase activity was obtained by measuring the extent of the hydrolysis of DHC, using a 
spectrophotometric method adapted for a 96-well microplate. Serum or plasma samples were diluted 
in the proportion of 1:5 in physiological serum and then 10 µL were added to each well. The samples 
and also the previous prepared standards were incubated a 37 ºC, during 10 minutes, where upon 
190 µL of freshly prepared HEPES buffer (2.0 mM, at pH 8.0) containing CaCl2 (1.0 mM), BSA 
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(0.005%), phenol red (106 µM) and DHC (1.0 mM) (Sigma-Aldrich) were added per well. Then, after 1 
minute of incubation at room temperature, the absorbance at 405 nm was measured on a microplate 
reader. The activity was directly obtained from the calibration curve and expressed as kU/L, which is 
defined as the amount of enzyme producing 1 mM of o-HPPA per minute. All samples/standards were 
analyzed in triplicate. 
 
iv. Method validation 
 
For the validation of this method, the same guidelines were used as for the method for the AREase 
activity assessment. 
 
Linearity 
The same procedure was applied, as it was for the method developed to quantify the AREase 
activity of PON1. The concentrations from the calibration curve ranged from 1.29 mM (LLOQ) to 10.24 
(HLOQ). 
 
Lower limit of quantification 
The same procedure was applied, as it was for the method for the AREase activity assessment 
method, using the concentration of 1.29 mM as the LLOQ. 
 
Accuracy 
The same procedure was applied, as it was for the AREase activity quantification method. The 
QC1 and QC2 concentrations were 4.92 mM and 6.55 mM, respectively. 
 
Precision 
Intra-assay and inter-assay precisions 
The same procedure was applied, as it was for the method to monitor the AREase activity. 
 
 
2.2.3 Paraoxonase activity of PON1 
 
The POase activity was assessed through the quantification of p-nitrophenol formation, as 
previously described by Batuca et al. (Batuca et al., 2007). Briefly, paraoxon (1.0 mM) (Sigma-Aldrich) 
freshly prepared in 290 µL of 50 mM glycine buffer containing 1 mM CaCl2 (pH 10.5) was incubated 
with 10 µL of sample, at 37 °C, for 10 min, in 96 well plates (Polysorp). P-nitrophenol formation was 
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monitored at 412 nm and the activity was expressed as µmol p-nitrophenol, per mL of serum, per 
minute. 
 
 
2.2.4 Blood sampling conditions definition 
 
A group of five healthy volunteers were included for the definition of blood sampling conditions for 
the development and validation of the PON1 activities methods. Blood samples were collected from 
five healthy volunteers by venipuncture. Three types of samples were obtained: a) blood collected 
without anticoagulants, b) blood collected with lithium heparin and c) blood collected with 
ethylenediaminetetra-acetic acid (EDTA). Serum or plasma were aliquoted after centrifugation and 
then stored at -80 °C until analysis. 
 
 
2.3 Effect of chronic exposure of nevirapine on PON1 activities in 
HIV-infected patients 
 
2.3.1 Quantification of nevirapine and its phase-I metabolites in plasma 
of HIV-infected patients  
 
The extraction and quantification of NVP and its phase-I metabolites was performed as previously 
described (Marinho et al., 2013). Briefly, the analytes were extracted from plasma previously heated at 
60 ºC for 60 minutes for viral inactivation, with dichloromethane (VWR, Radnor, PA). NVP was 
obtained from Cipla (Maharashtra, India) and the 2-OH, 3-OH, 8-OH, and 12-OH-NVP metabolites 
were synthesized at Instituto Superior Técnico, as already described (Grozinger et al., 2000; Antunes 
et al., 2011). 
High-performance liquid chromatography (HPLC) analyses was performed on an Agilent 1100 
Series system (Agilent Technologies, Santa Clara, CA) using a reversed-phase Luna C18 (2) column 
(250 mm × 4.6 mm; 5 μm; Phenomenex, Torrance, CA). The column temperature was 40 ºC, the 
injection volume was 100 µL, and ultraviolet (UV) absorbance was monitored at 254 nm. For each 
analyte, the LLOQ of the method was 10 ng/mL. 
 
2.3.2 Quantification of PON1 activities 
 
The three activities of PON1 were quantified, using the procedures already described in the 
previous sections, in serum samples of the selected HIV-infected population. 
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2.4 Statistical analysis  
 
Statistical analysis was performed using GraphPad Prism
®
 version 5.0 (Motulsky, 2007). Data was 
expressed as mean ± standard error of the mean (SEM), median [interquartile range, IQR] or 
frequencies (%), whenever applicable. The test of Pearson or the test of Spearman were used to 
explore correlations. Comparisons among groups were performed using One-way ANOVA, Student 
t-test or Mann Whitney U test, whenever applicable. The F-test was used to explore differences 
between the slopes and the elevations of the calibration curves in the validation of the methods. 
Variability among data was expressed in variation coefficient (CV), expressed as %. 
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3.  Results 
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3.1 Development and validation of PON1 activities methods 
 
3.1.1 Arylesterase activity of PON1 
i. Linearity 
The r
2
 of the 3 calibration curves was 0.997 ± 0.003. There were no differences between the 
slopes and the elevations of the calibration curves. 
 
ii. Lower limit of quantification 
The accuracy and precision of the LLOQ were calculated in the next sub-sections and are 
presented in Table 3.1. 
 
iii. Accuracy 
The accuracy values obtained for the QC1, QC2 and HLOQ were between 90% and 103% 
(Table 3.1). 
 
iv. Precision 
Intra-assay precision 
The values obtained for the intra-assay precision were higher than 94% (Table 3.1).  
The AREase activity of the serum sample from the healthy volunteer was 115 kU/L, and the 
intra-assay precision was 97%. 
 
Inter-assay precision 
The inter-assay precision for all the samples evaluated was higher than 92% (Table 3.1). 
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Table 3.1 Accuracy, intra-assay precision and inter-assay precision of the method for the 
arylesterase activity quantification. 
Standard  
(mM) 
Accuracy  
(%) 
Intra-assay precision 
 (%) 
Inter-assay precision  
(%) 
LLOQ (5.50) 90 94 92 
QC1(12.58) 103 96 96 
QC2 (16.78) 102 95 96 
HLOQ (26.21) 100 98 97 
LLOQ – lower limit of quantification; QC1 – quality control 1; QC2 – quality control 2; 
HLOQ - higher limit of quantification. 
 
 
3.1.2 Lactonase activity of PON1 
 
i. Linearity 
The r
2
 of the 3 calibration curves was 0.999 ± 0.0002 and there were no differences between 
the slopes and the elevations of the calibration curves. 
 
ii. Lower limit of quantification 
The accuracy and precision of the LLOQ are presented in Table 3.2. 
 
iii. Accuracy 
The accuracy values obtained for the QC1, QC2 and HLOQ were between 94% and 102% 
(Table 3.2). 
 
iv. Precision 
Intra-assay precision 
The values obtained for the intra-assay precision were higher than 93% (Table 3.2). The 
serum LACase activity of the healthy volunteer was 17 kU/L, and the intra-assay precision was 
94%. 
 
Inter-assay precision 
The inter-assay precision was higher than 92% for all the controls tested (Table 3.2). 
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Table 3.2 Accuracy, intra-assay precision and inter-assay precision of the method for the 
lactonase activity quantification. 
Standard  
(mM) 
Accuracy  
(%) 
Intra-assay precision  
(%) 
Inter-assay precision  
(%) 
LLOQ (1.29) 98 93 92 
QC1(4.92) 102 96 94 
QC2 (6.55) 97 98 97 
HLOQ (10.24) 94 96 96 
LLOQ – lower limit of quantification; QC1 – quality control 1; QC2 – quality control 2; 
HLOQ - higher limit of quantification. 
 
 
3.2 Blood sampling conditions definition 
 
In the current study, the serum, heparinized plasma and EDTA-plasma samples obtained 
from five healthy volunteers, were used to quantify the AREase, LACase and POase activities 
of PON1, in order to optimize and validate the blood sampling. The five volunteers were all 
caucasians, with ages between 22 and 27 years old and four were female. 
 
3.2.1 Quantification of the PON1 activities 
 
The different PON1 activities of the three samples tested are presented on Table 3.3. For 
the assessment of the effect of the anticoagulants used, the value of each activity obtained in 
serum samples was considered as 100%. The three activities were not influenced by heparin, 
while EDTA strongly inhibited all of them. Moreover, the male volunteer had the lowest AREase 
(47 kU/L for serum, 53 kU/L for heparinized plasma and 34 kU/L for EDTA-plasma) and LACase 
(9 kU/L for serum, 8 kU/L for heparinized plasma and 7 kU/L for EDTA-plasma samples) 
activities, though its POase activity had the highest values on the three samples (298 U/L for 
serum, 270 U/L for heparinized plasma and 148 U/L for EDTA-plasma samples). 
There was a direct correlation between each one of the PON1 activities of serum and 
heparinized plasma (Pearson r=0.999, p<0.0001 for the AREase activity; Pearson r=0.992, 
p<0.0001 for the LACase activity and Pearson r=0.972, p=0.006 for the POase activity). 
However, this association failed to be proved for EDTA samples. 
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Table 3.3 Blood sampling conditions and PON1 activities. 
  Sample 
 
Parameter 
(Unit) 
Serum Heparinized plasma EDTA plasma 
AREase 
Activity  
(kU/L) 
106 ± 34 107 ± 32 43 ± 11 
p-value* - NS <0.05 
Inhibition 
(%) 
- NS 55 ± 17 
LACase 
Activity  
(kU/L) 
17 ± 5 14 ± 4 10 ± 2 
p-value* - NS <0.05 
Inhibition 
(%) 
- NS 38 ± 14 
POase 
Activity  
(kU/L) 
243 ± 41 228 ± 37 152 ± 61 
p-value* - NS <0.05 
Inhibition 
(%) 
- NS 38 ± 19 
NS: non-significant; *One-way ANOVA with Bonferroni post test for multiple comparisons. 
(AREase – arylesterase; LACase – lactonase; POase – paraoxonase; EDTA - 
ethylenediaminetetra-acetic acid) 
 
 
3.2.2 Evaluation of the association among the different PON1 
activities in the different conditions tested 
 
The POase activity was not related to the AREase or LACase activity in any of the different 
conditions tested. The same result was found regarding EDTA inhibition. Although, a strong 
association was found between the AREase and LACase activities in serum (Pearson r=0.950, 
p=0.014) and heparinized plasma samples (Pearson r=0.955, p=0.012), but not in EDTA 
samples. 
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3.3 Effect of chronic exposure of nevirapine on PON1 activities in 
HIV-infected patients 
3.3.1 Anthropometric and clinical data of the included patients 
 
A total of fifty-four HIV-infected patients (30 men) were included in this study. Thirty-two 
patients were Caucasian, twenty-one were African and 1 was Indian. Only 2 patients had 
detectable viral load. The patient’s anthropometric and clinical data are shown in Table 3.4. 
 
Table 3.4 Anthropometric and clinical data from the included patients. 
Parameter (Unit) Value 
N 54 
Proportion of men (%) 56 
Proportion of non-Caucasians (%) 41 
Age (years) 
a 
46 [39-55] 
Body weight (kg) 
b,
 69 ± 2  
Height (m) 
b,
 1.68 ± 0.01 
BMI (kg/m
2
) 
b, 
 25 ± 1 
Time on NVP (months) 
a
 42 [23-84] 
HDL (mg/dL) 
a
 60 [47-68] 
LDL (mg/dL) 
a, c
 124 [77-154] 
TG (mg/dL) 
a
 105 [68-139]  
TC (mg/dL) 
a
 202 [170-221]) 
CD4 T-cells count (cell/mm
3
) 
a
 538 [378-680] 
a 
Median[IQR]; 
b
 Mean ± SEM; 
c
 only 15 patients had available data for this 
parameter (N – number; BMI – body mass index; NVP – nevirapine; HDL – 
high-density lipoprotein; LDL – low-density lipoprotein; TG – triglyceride; TC – 
total cholesterol; CD4 – cluster of differentiation 4) (ideal values: HDL 42 - 88 
mg/dL; LDL < 130 mg; TG: 40 – 150 mg/dL; TC <200 mg/dL) 
 
 
3.3.2 Quantification of nevirapine and its phase-I metabolites 
 
NVP and its phase-I metabolites concentrations are presented in Table 3.5. All patients had 
8-OH-NVP levels below the quantification limit of the HPLC method. 
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Table 3.5 Nevirapine and its phase-I metabolites concentrations. 
Analytes  
Concentrations 
a
 
(ng/mL) 
NVP 
a
 4,137 [3,388-4,991] 
2-OH-NVP 
a, b
 55.0 [24.2-106.8] 
3-OH-NVP 
a
 25.5 [17.6-35.7] 
12-OH-NVP 
a
 371.0 [250.7-513.7] 
a 
Median[IQR]; 
b 
for 2-OH-NVP, only 29 patients had quantifiable 
concentrations. (NVP – Nevirapine; 2-OH-NVP – 2-hydroxy-nevirapine; 
3-OH-NVP – 3-hydroxy-nevirapine; 12-OH-NVP - 12-hydroxy-nevirapine) 
 
 
3.3.3 Influence of anthropometric and clinical data of patients on 
nevirapine and its metabolites concentrations 
 
The influence of body weight and body mass index (BMI) as well as time on NVP-containing 
cART on the concentrations of NVP and its phase-I metabolites was assessed and is 
represented in Table 3.6. 
 
Table 3.6 Influence of body weight, body mass index and time on 
nevirapine-containing combined antiretroviral therapy on nevirapine and its phase-I 
metabolites. 
Parameter  
(Unit) 
ng/mL 
NVP 2-OH-NVP 3-OH-NVP 12-OH-NVP 
Body weight  
(kg) 
NS NS 
↓ r=-0.482,
 
 
p<0.001 
a
 
NS 
BMI  
(kg/m
2
) 
↑ r=0.295, 
p=0.042 
b
 
↓ r=-0.423, 
p=0.044 
a
 
↓ r=-0.290, 
p=0.046 
a
 
NS 
Time on NVP  
(months) 
NS NS NS NS 
a 
Spearman correlation; 
b 
Pearson correlation; NS – non significant (NVP – nevirapine; 
2-OH-NVP – 2-hydroxy-nevirapine; 3-OH-NVP – 3-hydroxy-nevirapine; 12-OH-NVP – 
12-hydroxy-nevirapine; BMI – body mass index; NVP - nevirapine) 
 
Though both body weight and BMI might have an influence on nevirapine and its phase-I 
metabolites, time on NVP seemed to have no influence on them. 
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3.3.4 Assessment of the possible relations among the three 
activities of PON1 in HIV-infected patients 
 
The activities of PON1 enzyme were quantified in all included patients and its mean values 
are presented in Table 3.7. A positive correlation was found between the AREase and POase 
activities (Spearman r=0.335, p=0.014) and also between the AREase and LACase activities 
(Spearman r=0.773, p<0.0001) (Fig. 3.1). Even though there was a relation between the 
AREase and POase activities, the relation between the AREase and LACase activities was 
stronger. No such correlation was found between the POase and LACase activities (Table 3.8). 
 
Table 3.7 PON1 activities in serum samples. 
PON1 activities Value 
AREase  
(kU/L) 
a
 
80 ± 35 
LACase  
(kU/L) 
a
 
14 ± 8 
POase  
(U/L) 
a
 
211 ± 61 
a 
Mean ± SEM (PON1 – paraoxonase-1; AREase – 
arylesterase; LACase – lactonase; POase – 
paraoxonase) 
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Figure 3.1 Correlation between PON1 AREase and LACase activities 
in serum samples of HIV-infected patients. (Spearman r=0.773, 
p<0.0001) 
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Table 3.8 Relations between the three activities of PON1. 
 
AREase 
(kU/L) 
LACase 
(kU/L) 
POase  
(U/L) 
↑ r=0.335, 
0.014 
a
 
NS 
AREase 
(kU/L) 
NA 
↑ r=0.773, 
p<0.0001 
a
 
a 
Spearman correlation; NS – non significant; NA – not applicable 
(POase – paraoxonase; AREase – arylesterase; LACase – lactonase) 
 
 
3.3.5 Association between the anthropometric and clinical data from 
the included patients and PON1 activities 
 
The three assessed PON1 activities were associated with clinical data of the patients. The 
obtained results are presented in Table 3.9. 
Regarding PON1 AREase activity, no significant sex differences were found. The activity 
was slightly correlated with age (Spearman r=-0.366, p=0.007), body weight (Pearson r=0.369, 
p=0.008) and BMI (Pearson r=0.337, p=0.017).  
PON1 AREase activity was also positively correlated with HDL (Spearman r=0.326, 
p=0.022), TG (Pearson r=0.501, p=0.0002), TC (Spearman r=0.302, p=0.033) and negatively 
correlated with time on NVP treatment (Pearson r=-0.402, p=0.003).  
 
For the LACase activity, no differences were found between women and men. On the other 
hand, a negative correlation was found between the activity and ageing (Spearman r=-0.293, 
p=0.039) and time on NVP-treatment (Spearman r=-0.294, p=0.038). Positive correlations were 
found for TG (Pearson r=0.531, p=0.0001), TC (Spearman r=0.321, p=0.026) and CD4 T-cells 
count (Pearson r=0.301, p=0.036).  
 
As for the POase activity, a higher activity was found among women in comparison with men 
(p=0.032), but no effects of age were found. The activity was found to decrease with the 
increment of body weight (Spearman r=-0.289, p=0.042), though no correlation was found with 
BMI. Regarding clinical data, no correlation was found between the activity and LDL, TC and 
TG concentrations as well as with time on NVP treatment and CD4 T-cells count. A positive 
correlation was found between the activity and HDL concentration (Spearman r=0.290, 
p=0.044). 
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Table 3.9 Possible relations between the anthropometric and clinical data and 
PON1 activities 
Parameter 
(Unit) 
AREase 
(kU/L) 
LACase 
(kU/L) 
POase 
(U/L) 
Gender NS NS p=0.032 
c
 
Ethnicity NS NS NS 
Age 
(Years) 
↓ r=-0.366, 
p=0.007 
b
 
↓ r=-0.293, 
p=0.039 
a
 
NS 
Weight  
(kg) 
↑ r=0.369, 
p=0.008 
b
 
NS 
↓ r=-0.289, 
p=0.042 
a
 
BMI 
(kg/m
2
) 
↑ r=0.337, 
p=0.017 
b
 
NS NS 
Time on NVP 
(months) 
↓ r=-0.402, 
p=0.003 
b
 
↓ r=-0.294, 
p=0.038 
a
 
NS 
CD4 T-cells 
(cell/mm
3
) 
NS 
↑ r=0.301, 
p=0.036 
b
 
NS 
HDL 
(mg/dL) 
↑ r=0.326, 
p=0.022 
a
 
NS 
↑ r=0.290, 
p=0.044 
a
 
LDL 
(mg/dL) 
NS NS NS 
TG 
(mg/dL) 
↑ r=0.501, 
p<0.001 
b
 
↑ r=0.531, 
p<0.001 
b
 
NS 
TC 
(mg/dL) 
↑ r=0.302, 
p=0.033 
a
 
↑ r=0.321, 
p=0.026 
a
 
NS 
a 
Spearman correlation; 
b 
Pearson correlation; 
c
 Mann Whitney U test; NS – non 
significant (AREase – arylesterase; LACase – lactonase; POase – paraoxonase; BMI 
– body mass index; NVP – nevirapine; CD4 - cluster of differentiation 4; HDL – 
high-density lipoprotein; LDL – low-density lipoprotein; TG – triglycerides; TC – total 
cholesterol) 
 
3.3.6 Relationship between the assessed analytes and PON1 
activities 
 
The results obtained for the association between the PON1 activities and the concentrations 
of NVP and its phase-I metabolites are presented in Table 3.10. 
The metabolite 3-OH-NVP seemed to have no influence, whilst 12-OH-NVP was the 
metabolite with the highest negative influence on the three PON1 activities (Spearman r=-0.305, 
p=0.031 for the AREase activity, Spearman r=-0.342, p=0.019 for the LACase activity and 
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Spearman r=-0.284, p=0.044 for the POase activity). Moreover, the effect of both metabolites 
2-OH and 12-OH-NVP was more pronounced than the effect of NVP by itself.  
As the LACase activity was only influenced by 12-OH-NVP, we thought to study the 
proportions of this metabolite. In fact, we found a high variability on 12-OH-NVP proportions, 
and patients who had lower formation of this metabolite had higher AREase and LACase 
activities (Pearson r=0.452, p=0.001 for the AREase activity, and Pearson r=0.292, p=0.044 for 
the LACase activity). Moreover, no differences were found between patients who had 2-OH-
NVP concentrations above or below the limit of quantification on the three activities. 
 
NVP or its phase-I metabolites were not correlated with HDL levels. Since 3-OH-NVP was 
the only analyte correlated with body weight, the relations between the three activities and 
3-OH-NVP concentrations adjusted for body weight were also explored. However, no correlation 
was found. 
 
Table 3.10 Correlations found between the analytes concentrations and 
PON1 activities. 
Parameters 
(Unit) 
AREase 
(kU/L) 
LACase 
(kU/L) 
POase 
(U/L) 
NVP 
(ng/mL) 
↓ r=-0.294, 
p=0.036 
a
 
NS 
↓ r=-0.290, 
p=0.037 
a
 
2-OH-NVP 
(ng/mL) 
↓ r=-0.461, 
p=0.023 
a
 
NS 
↓ r=-0.450, 
p=0.028 
b
 
3-OH-NVP 
(ng/mL) 
NS NS NS 
12-OH-NVP 
(ng/mL) 
↓ r=-0.305, 
p=0.031 
a
 
↓ r=-0.342, 
p=0.019 
a
 
↓ r=-0.284, 
p=0.044 
a
 
NVP:12-OH-NVP 
↑ r=0.452, 
p=0.001 
b
 
↑ r=0.292, 
p=0.044 
b
 
NS 
a 
Spearman correlation; 
b 
Pearson correlation; NS – non significant (AREase – 
arylesterase; LACase – lactonase; POase – paraoxonase; NVP – nevirapine; 
2-OH-NVP – 2-hydroxy-nevirapine; 3-OH-NVP – 3-hydroxy-nevirapine; 12-OH-
NVP – 12-hydroxy-nevirapine) 
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4.  Discussion 
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For the assessment of the quality of HDL in HIV-infection, a two-part study was herein 
undertaken. The first part was regarded to the development of new methods for the assessment 
of the AREase and LACase activities of PON1. 
The development of microplate-based methods has allowed a high-throughput measurement 
of PON1 activity using paraoxon as substrate (Beltowski et al., 2002; Naderi et al., 2011). The 
same can be applied for the other identified activities of PON1, namely the AREase and 
LACase activities, avoiding in turn the use of higher amounts of both biological sample and 
remaining reagents. 
In the present study, two simple, fast and inexpensive methods suitable for the measurement 
of the AREase and LACase activities of PON1 enzyme in human blood were developed and 
validated. These methods are capable of measuring the two activities in several samples 
simultaneously, using a very small amount of biological fluid and remaining solutions, which is a 
major advantage especially for research purposes, where the volume of the samples available 
is a serious limitation. Furthermore, as the assays are not performed at an UV, but at a visible 
spectrum range (405 nm), the use of quartz microplates is not required. The enzymatic kinetic 
can be performed in a spectrophotometer available at any research/clinical facility. 
Regarding the AREase activity, the current available methods for its assessment monitor the 
formation of phenol at an UV range. However, the quantification of acetic acid instead of phenol 
allows the use of simple titration based-methods that can be monitored at a visible range, thus 
being unnecessary the use of sophisticated and expensive spectrophotometers, which might 
not be available in clinical routine labs. The enzymatic assay herein described is based on a 
method initially proposed by Sharp and Rosenberry (1982) for the measurement of the kinetic 
properties of acetylcholinesterase with its physiological substrate, acetylcholine (Sharp and 
Rosenberry, 1982). As in the hydrolysis of acetylcholine, the hydrolysis of phenyl acetate by 
PON1 produces acetic acid in stoichiometric amounts to the substrate degradation. By including 
a pH indicator dye such as phenol red, the color change resulting from the production of acetic 
acid can be monitored spectrophotometrically in the visible range and be directly related with 
the AREase activity. However, the use of phenol, which in turn is toxic and photoreactive, can 
be set as the major drawback of the proposed method. The use of toxic substrates is a 
handicap of PON1 measurement, as paraoxon is also toxic, requiring the use of appropriate 
safety precautions, such as wearing mask and gloves to protect against accidental contact or 
inhalation of the toxic fumes (Pereira et al., 2009). 
The enzymatic assay here proposed for the LACase activity of PON1 was also based on the 
same phenol red assay of Sharp and Rosenberry (Sharp and Rosenberry, 1982), modified later 
by Billecke and co-authors, in 1999 (Billecke et al., 1999; Billecke et al., 2000). Herein, the fact 
that the hydrolysis of DHC also produces an acid, the o-HPPA, was taken as an advantage. 
Likewise, the o-HPPA is produced in stoichiometric amounts to the degradation of DHC, which 
can be monitored spectrophotometrically in the visible range. 
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The levels obtained for the AREase and LACase activities in the serum samples of the 
healthy volunteers were found to be similar to the ones already obtained in other studies, which 
for the AREase activity had monitored phenol formation (Hernández et al., 2009). These 
methods have applicability in plasma and serum samples, and since PON1 enzyme is 
associated with circulating HDL, the blood would be the main fluid of interest. However, these 
methods could possibly be adapted, with suitable changes, for other sample types, such as cell 
culture supernatants and even cerebrospinal fluids, further showing its applicability for clinical 
and research proposes. 
An aspect there is sometimes mistreated is the blood sampling conditions, which for the 
case of PON1 activities assessment is very imperative. The enzyme activities measured in 
plasma are often lower than those measured in serum samples, due mainly to the ability of fibrin 
clots to retain a certain amount of water, resulting in a higher concentration of analytes in serum 
(Mackness, 1998b; Guthold et al., 2004). Although, we showed that both methods are suitable 
for serum and heparinized plasma samples. To the best of our knowledge, this relationship was 
only previously demonstrated for the POase activity (Ferre et al., 2005; Araoud et al., 2011). 
Whereas serum is the preferred sample for the measurement of the POase activity, previous 
reports classified the effect of lithium-heparin on POase activity measurement as negligible 
(Ferre et al., 2005). Several groups have reported studies on the POase activity in 
lithium-heparin-treated samples, and the results were lower but consistent with those obtained 
in serum samples (Jarvik et al., 2002; Martín-Campos et al., 2002). In the present study, the 
three activities measured in heparinized plasma were consistent with the ones obtained in 
serum samples, showing that the lithium-heparin-treatment has no significant influence on the 
AREase and LACase besides the POase activities of PON1 enzyme. 
On the other hand, the present data showed that EDTA-containing samples should be 
completely avoided. The three activities of PON1 require calcium for their function (Kuo and La 
Du, 1998; Billecke et al., 2000). The use of the anticoagulant EDTA is well known as unsuitable 
for the POase activity assay (Erdös and Boggs, 1961; Mackness, 1998a). In fact, EDTA-plasma 
samples had lower POase activity than serum samples by 38%, and was consistent with 
previous published studies using patients samples, with a mean inhibition of 41% (Araoud et al., 
2011). Moreover, a similar inhibition percentage was also found in studies using the purified 
PON1 enzyme (Golmanesh et al., 2008). This decrease on activity was not dependent on the 
activity per se, nor related to the activity in serum or heparinized plasma samples. Given that 
PON1 requires calcium for both activity and stability, the presence of calcium chelators (e.g. 
EDTA and citrate) as anticoagulants is expected to inhibit its activities. Therefore, the inhibition 
of PON1 by EDTA has been reported for the measurement of the activities of the enzyme using 
a variety of substrates (Erdös and Boggs, 1961). Herein it was for the first time found that this 
inhibition is even more pronounced for the AREase activity, and for the LACase activity has a 
similar effect to the one found for the POase activity. As such, in studies where PON1 is 
involved, the blood collection conditions should be carefully defined and the use of plasma 
samples collected with EDTA should be avoided. 
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Lastly, when exploring the possible relations between the three different PON1 activities, the 
POase activity was not related with the AREase and LACase activities in the three different 
blood sampling conditions tested. The AREase and LACase activities were highly correlated. 
Despite data are conflicting on this issue (Nevin et al., 1996; Camuzcuoglu et al., 2009; 
Camuzcuoglu et al., 2011), structure-activity studies might give some clues for this evidence. 
Firstly, a histidine dyad composed of His
115
 and His
134
 was suggested to be directly involved in 
the catalytic mechanism of PON1 for both ester (e.g. phenyl acetate) and phosphotriester (e.g. 
paraoxon) hydrolysis. Mutagenesis experiments support this mechanism although it was later 
found that these mutants were probably misfolded and, therefore, inactive (Harel et al., 2004), 
undermining these results. Subsequently, Khersonsky and Tawfik (2006) showed, by 
site-directed mutagenesis, that the LACase and AREase activities were both mediated by the 
His
115
-His
134
 dyad and that notably, the POase activity, which is a promiscuous activity of PON1, 
is mediated by other residues (Khersonsky and Tawfik, 2006). This evidence might explain the 
absence of relation between the POase activity and the two other activities and also the relation 
found between the AREase and LACase activities. 
 
On the second part of this study the developed methods were applied into a cohort of 
HIV-infected patients that were under NVP-containing cART for at least one month. Besides its 
low cost and the efficient prevention of mother-to-child HIV-1 transmission, NVP has 
consistently been linked with a better lipidic profile in comparison with other antiretroviral drugs 
(van der Valk et al., 2001; van Leth et al., 2004). NVP has also been widely used in the 
simplification of PI-containing therapy (Harris, 2003), and the risk of major toxicities in this 
setting seems to be lower than in naïve patients (Mocroft et al., 2007). Moreover, NVP was 
found to have a protective role on pre-diabetes (Srivanich et al., 2010). 
In the present study, no correlation was found between NVP concentrations and body 
weight. Several published studies, though not all of them (De Matt et al., 2002), support the idea 
that body weight has no effect on NVP concentration (Kappelhoff et al., 2005; Stöhr et al., 2008; 
Marinho et al., 2013). Additionally, only the concentrations of 3-OH-NVP were negatively 
correlated with body weight. The concentrations of 2-OH-NVP and 3-OH-NVP decreased with 
the increment of BMI, while NVP levels increased. As NVP is a highly lipophilic drug (Mirochnick 
et al., 2000), it distributes readily across tissues and might probably accumulate on the less 
perfused tissues such as the fat tissue, further leading to an increase in its concentration. 
Nevertheless, NVP concentrations were previously reported to be reduced with higher BMI 
levels (Autar et al., 2005). As for the PON1 activities, previous reports but not all of them 
(Abbott et al., 1995; Veiga et al., 2011), have shown a decrease of serum PON1 in obese 
patients (Ferretti et al., 2005; Bajnok et al., 2007; Bajnok et al., 2008; Ozenoglu et al., 2008; 
Ferretti et al., 2010; Aslan et al., 2011; Ferretti et al., 2012a). In this study, the POase activity 
was decreased in patients with higher body weight, whilst the AREase activity was positively 
correlated with both body weight and BMI. A possible explanation for these results is the fact 
that only five patients had BMI levels higher than 30 kg/m
2
, the number from which above a 
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person is considered to be obese (WHO, 1995), with the higher value observed of 33 kg/m
2
, 
further suggesting that the selected population was not considered obese at all. However, no 
relation was found between PON1 and NVP and its phase-I metabolites concentrations when 
adjusting by body weight and BMI. 
 
NVP has the capacity to increase HDL levels, in a way that the current available drugs for 
this purpose cannot: fibrates and statins have been associated with modest HDL changes 
(Birjmohun et al., 2005) and niacin showed a moderate increase in HDL levels, but with no 
clinical benefits (Filippatos and Elisaf, 2013). The ability of NVP to increase HDL levels is 
indisputable, but the question of its quality is also a debatable issue. 
Regarding the relation between the three PON1 activities assessed in HIV-patients, they 
were different from the ones found for the healthy volunteers. The POase activity was positively 
correlated with the AREase but not with the LACase activity. Moreover, the AREase and 
LACase activities were highly correlated. The relation found between the POase and AREase 
activities is consistent with previous reported studies in other pathological conditions 
(Camuzcuoglu et al., 2009; Camuzcuoglu et al., 2011; Ferretti et al., 2012b). Also, a similar 
relation was found for the POase and LACase activities (Ferretti et al., 2012b; Sztanek et al., 
2012). As so, it is possible to assume that there are different relations between the activities of 
PON1 in healthy and in pathological states, which can be probably due to an unknown 
mechanism that could change the structure of PON1 and, consequently, its activities. Moreover, 
the results of PON1 activities may depend on the methods used as well as the disease studied, 
hence the necessity to explore all its activities and standardize substrate and methods to 
explore them as possible disease biomarkers (Parra et al., 2010b).  
 
The fact that PON1 enzyme activities and levels vary broadly in humans (Costa et al., 
2005b) needs to be taken into account. Several differences were found between the different 
assessed activities when correlating them with anthropometric and clinical data from the HIV 
population. For instance, regarding sex differences, though the AREase and LACase activities 
were also higher in women than in men, only the POase activity was found to be statistically 
significant. Results from previous human and animals studies show that females have higher 
PON1 activity than males (Mueller et al., 1983; Kleemola et al., 2002; Rainwater et al., 2005; 
Birjmohun et al., 2009; Eom et al., 2011). This higher levels are thought to be caused, for 
instance, by oral contraceptives intake (Rainwater et al., 2009), which are mainly composed by 
estrogens. Though among the HIV population, the values of HDL are reported to be higher in 
women (El-Sadr et al., 2005), the fact that NVP is as well more toxic on them (Marinho et al., 
2013) can be an excuse for the results found for the AREase and LACase activities, which are 
considered more physiological activities than the POase activity.  
It is already known that serum PON1 levels and activities vary widely among diverse ethnic 
populations (Mohamed Ali and Chia, 2008), due mainly to genotypic differences (Sanghera et 
al., 1997; Sanghera et al., 1998; Poh and Muniandy, 2007), with the caucasian population 
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having lower values of the POase activity (Pereira et al., 2009). However, on this study no 
differences were found between the ethnic groups, and yet nearly half population was 
non-caucasian. On the other hand, ageing was correlated with a decrease in both the AREase 
and LACase activities, which in turn was not observed in the POase activity. The negative effect 
of ageing on PON1 activities has been consistently reported (Jarvik et al., 2002; Seres et al., 
2004; Cherki et al., 2007; Ayotte et al., 2011) and has been attributed to an increase in oxidative 
stress in the elderly population (Jaouad et al., 2006). As so, this effect is expected to be more 
pronounced in the AREase and LACase activities as they are responsible for the detoxification 
of endogenous toxic compounds, oxidized lipids and HcyTL, respectively, which are known to 
be linked to this condition (Sentí et al., 2003; Ferretti et al., 2005; Rosenblat et al., 2006; 
Mendes et al., 2010; Bharathselvi et al., 2013). 
 
In what concerns the lipid parameters, the positive association between the AREase and 
POase activities and HDL was expected since PON1 is associated with this lipoprotein in the 
circulation (Sorenson et al., 1999). This relation has been reported in other studies involving 
HIV-infected patients (Parra et al., 2010b) healthy subjects (Ferre et al., 2003; Boesch-
Saadatmandi et al., 2010), smokers (Mouhamed et al., 2010) and also in clinical conditions 
where the lipidic profile is altered, including familial hypercholesterolemia (van Himbergen et al., 
2005). Though the lack of association between the LACase activity and HDL levels was a 
surprise, it was already reported (Gugliucci et al., 2011). A possible explanation could be the 
fact that since HDL metabolism is impaired in HIV-infection, its relation with the three activities 
of PON1 can also be affected. 
On the other hand, no correlation was found between the activities and LDL levels, though 
the inverse was already reported (Kotani et al., 2009). In our study, only fifteen patients had 
reported LDL levels, which can probably undermine the nonexistence of such correlation. No 
further associations between the POase activity and other lipid parameters were observed, 
which was consistent with previous studies (Sumegová et al., 2007; Toy et al., 2009). 
Correlations between TG and TC were found for both AREase and LACase activities. These 
correlations could be expected, as these activities are considered the physiological ones. 
However, the fact that the mean TG levels among the population were not extremely high needs 
to be taken into account. 
A negative correlation between the AREase and LACase activities and time on 
NVP-containing cART was found, which, to the best of our knowledge, was never reported. As 
the initiation of NVP needs to be carefully monitored with CD4 T-cell count (Leith et al., 2005), 
the effect of this parameter on PON1 activities was also explored, though only the LACase 
activity was related with it. Relations between CD4 T-cell count and the POase activity were 
previously described by our group (Pereira et al., 2009) and others (Parra et al., 2007), though 
the studied populations were under different cART regimens, which can induce differences on 
the these parameter. This positive relation between CD4 T-cell count and the LACase activity 
further indicates lower PON1 activities is associated with a more severe infection. 
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Though NVP was already found to raise HDL levels in HIV-infected patients, through an 
increase in Apo A-1 expression (Fisac et al., 2005), no such correlation was found in this study. 
However, as there was no access to the HDL baseline values, it is impossible to know if there 
was any kind of increment on its concentration since then. Our group has previously show that 
EFV only increased HDL levels in patients who had baseline value of HDL lower than 40 mg/dL 
(Pereira et al., 2006). In terms of raising the HDL quality, there was also some controversy, as 
the AREase and POase activities decreased with the increment of NVP, while no correlation 
was found with the LACase activity. These results can further demonstrate that although NVP 
could raise HDL in terms of quantity, its quality, as far as it concerns its antioxidant potential, 
could be quiet doubtful, supporting the current idea that HDL function is defective in this 
population (Parra et al., 2007; Daminelli et al., 2008; Pereira et al., 2009). 
The association between HIV-infection and HDL metabolism is already known. The depletion 
of the cholesterol efflux reduces the production of the viral particles (Ono and Freed, 2001). In 
macrophages, the HIV-1 negative regulatory factor (Nef) accessory protein inhibits the 
cholesterol efflux via ATP-binding cassette transporter (ABCA1) (Mujawar et al., 2006). 
Moreover, in HIV-infected patients, the concentrations and activities of both lecithin-cholesterol 
acyltransferase (LCAT) and cholesterylester transfer protein (CETP) are increased, which can 
divert the latter steps of RCT from delivery of cholesterol directly to the liver (Rose et al., 2008). 
Though the liver, through LDL receptors, will take up the majority of transferred cholesterol, the 
amount of cholesterol available for modification and uptake by extrahepatic tissues will also 
increase proportionally. If this situation persists over a long period of time, it can potentiate the 
development of atherosclerosis. These changes in HDL can be reflected on the activities and 
function of PON1 (Rose et al., 2008). 
 
Regarding NVP metabolism, there are many potential reactive metabolites inherited to the 
drug. In both humans and rats, the major metabolic pathways of NVP involve 2-, 3-, and 
12-hydroxylation (Riska et al., 1999a; Riska et al., 1999b). The first two are para-positions to a 
nitrogen atom, and further oxidation can lead to quinoneimine type reactive metabolites, whilst 
12-OH-NVP has the potential to be sulfated (e.g. 12-sulfoxy-NVP) followed by loss of sulfate to 
form a reactive quinone methide (Spahn-Langguth and Benet, 1992). Though the associations 
between the NVP and its phase-I metabolites and PON1 activities were never reported, several 
assumptions can be made. Firstly, the metabolite 3-OH-NVP seems to have no influence at all 
on the activities of PON1. On the other hand, 12-OH-NVP was found to reduce all the activities. 
Moreover, 2-OH-NVP concentrations were also found to reduce the AREase and POase 
activities. It was also possible to see that 2-OH and 12-OH-NVP had a more exacerbated toxic 
effect on the activities than NVP by itself, further supporting the idea that NVP is toxic upon its 
biotransformation (Caixas et al., 2012). When analyzing the absence of relation between NVP 
concentrations and the LACase activity, it was thought that this could be due to the variability in 
12-OH-NVP proportions among patients and also because it is the major NVP metabolite. In 
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fact, we found a 35% of variability on the proportions of the metabolite (data not shown), and 
patients who had lower 12-OH-NVP formation had higher LACase and AREase activities. As so, 
the negative correlation found between the activities and 12-OH-NVP concentrations and 
proportions was already expected, as this metabolite has been consistently associated with 
adverse-NVP reactions (Antunes et al., 2008; Chen et al., 2008; Antunes et al., 2010a; Antunes 
et al., 2010b; Caixas et al., 2012; Pereira et al., 2012; Marinho et al., 2013; Meng et al., 2013; 
Sharma et al., 2013).  
 
The study of PON1 in HIV-infection is still limited. Few studies are available, and the majority 
of them refers to the POase activity (Parra et al., 2007; Daminelli et al., 2008; Pereira et al., 
2009), which, as already mentioned, could not totally reflect the real physiological capacity of 
the enzyme. Moreover, most studies have inherited disadvantages, which can undermine their 
results, such as the inclusion of both patients treated for the first time and with cART experience 
and with different co-infections (e.g. hepatitis C). For instance, there were two studies 
describing that HIV-infected patients had lower PON1 POase activity than HIV-negative 
individuals, regardless of cART (Parra et al., 2007; Daminelli et al., 2008). A cross-sectional 
study on the POase activity in HIV-infected patients, concluded that EFV-containing cART 
increased the activity (Pereira et al., 2009). Recently, a study was published concluding that 
PON1 appeared to be a marker for the metabolic syndrome on HIV-infected patients (Bobin-
Dubigeon et al., 2013). Till this time, every study performed with PON1 had never been done 
correlations with the drugs or even its metabolites concentrations. For the LACase activity, there 
is one report regarding the DING proteins, which have been described as possessing anti-HIV 
activity (Berna et al., 2009). Apparently, these proteins share with PON1 a relation with the 
human phosphate binding protein (HPBP). Though not directly related with the study, they 
reported that there were no differences on the LACase activity assessed in HIV-infected 
patients and in healthy volunteers (Djeghader et al., 2012). However, it is needed to take into 
account that more than half patients were co-infected with hepatitis C. In 2010, Parra and 
colleagues also reported the methodological constraints in interpreting serum PON1 activity 
measurements. Both POase and LACase activities were higher in control subjects than in 
HIV-infected patients. They also concluded that the results of clinical studies on PON1 may vary 
depending on the methods used (Parra et al., 2010b). For the AREase activity, the information 
is even scarcer. Only one abstract from an oral presentation was found, reporting that the levels 
of AREase activity were lower than the value for healthy controls, further suggesting that 
immunosuppression in HIV-infected patients could affect PON1 and its subsequently antioxidant 
effect (Tungsiripat et al., 2012). 
 
In summary, two reproducible, reliable and suitable methods for the monitoring of the 
AREase and LACase activities of PON1 in human blood are here described. The methods allow 
the assessment of these activities on a large number of samples in a short period of time, which 
is especially advantageous for clinical application. As far as we know, this study reports, for the 
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first time, the effect of different blood sampling collection on the AREase and LACase activities. 
Currently, there are no new updates on what regards the substrates available for the 
measurement of the AREase activity. In what regards the LACase activity, HcyTL, which is the 
alleged physiological substrate of PON1, has only recently become available for purchase. 
However, concerning has been rising on whether or not this naturally endogenous substrate is 
appropriate for the measurement of PON1 enzyme activity (Yilmaz, 2012). This only could be 
verified by building up a new method using this substrate, which is currently underway. 
On the other hand, herein is also reported for the first time the effect of NVP and its phase-I 
metabolites on the activities of PON1. Though NVP is known as an HDL booster, in this study 
we saw a negative effect of the drug on PON1 activities, which might be due to the effect of its 
biotransformation products and not a particularly effect of the drug itself. It was clearly observed 
that the metabolite 3-OH-NVP had no influence on the activities of PON1, while 12-OH-NVP 
metabolite could be responsible for the noted decrease of the activities, once again proving the 
negative effects of this particular metabolite. Furthermore, it is plausible to assume that PON1 
could have a potential role on the detoxification of the toxicity state conferred by the 
bioactivation of the 12-OH-NVP metabolite, mainly because the enzyme has the capability to 
detoxify HcyTL, which can further led to adduct formation. On the other hand, as PON1 also 
contributes to the production of GSH, which is another antioxidant known to have an effect on 
adducts (Chung et al., 2005) (Fig 1.4). Further studies are needed in order to clearly unveil the 
mechanisms involved on this protective function, but the study of the three known PON1 
activities and the effect of different adducts-producing ARVs per se and in combination, namely 
other NNRTIs (EFV) or ABC, by probably an in vitro incubation, could be important in order to 
assess if the enzyme can, in fact, have a protective role against this toxicity.  
On the other hand, the field for developing new drugs with HDL-booster effects is an 
appealing area, as the current efforts have failed. For instance, torcetrapib, a CETP inhibitor, 
showed a unacceptable safety profile (Tall et al., 2007). Moreover, dalcetrapib, another CETP 
inhibitor, seems to have no influence on cardiovascular outcome (Filippatos and Elisaf, 2013).  
 
Along with the study of PON1 in HIV-infection and CVD and with the background acquired, 
the candidate attempted to study this enzyme in brain tumorigenesis process (Fig. 4.1), a 
project that is currently under review for a scholarship for the candidate, funded by Liga 
Portuguesa Contra o Cancro and Pfizer Laboratories. Briefly, it is possible to draw a square 
using oxidative stress, antioxidant thiols, lipid peroxidation and carcinogenic processes as 
vertices, and the role of PON1 on the dynamic of this cycle remains to be explored.  
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Figure 4.1 Schematic representation of the biochemical interactions where PON1 
can be a player in brain tumorigenesis. 
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